AZAlia Zehani

Alia Zehani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alia Zehani has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Phenotypic Profile of Microsatellite Stable with Epithelial to Mesenchymal Transition Subtype in Gastric Adenocarcinoma

    by Marwa Lakhal, Sarra Ben Rejeb, Alia Zehani, Slim Haouet, Maher Kharrat, Khadija Bellil

    The microsatellite stable with epithelial to mesenchymal transition (MSS/EMT) subtype includes some of the most aggressive gastric tumors with the worst prognosis. The purpose of this study is to characterize the MSS/EMT subtype by investigating potential associations with clinicopathologic features and specific elements of the tumor microenvironment: tumor-infiltrating lymphocytes and tumor budding. From a retrospectively collected bi-centric cohort, we first selected microsatellite stable samples and then assessed the immunohistochemical expression of E-cadherin, β-catenin, and zinc finger E-box binding homeobox 1 to identify the epithelial to mesenchymal transition. Our findings revealed that the MSS/EMT subtype represented 43% of our series, which was a high prevalence compared to previous studies. This subtype included patients who were significantly younger than non-MSS/EMT patients ( p =  .017). It was associated with diffuse and mixed-type histology ( p =  .047) and with nonconventional carcinomas ( p =  .023). The MSS/EMT did not correlate with the advanced stage. Regarding the tumor microenvironment elements, the MSS/EMT subtype was associated with low density of tumor-infiltrating lymphocytes ( p < 10 −3 ), while no association was found with tumor budding score. In conclusion, the highly prevalent and distinct MSS/EMT gastric cancer subtype features low tumor-infiltrating lymphocyte density, suggesting an immunosuppressive tumor microenvironment and therapy resistance.


  • Open Access

    Giant cell tumor of the temporal bone: two case reports and literature review

    by Khansa Abderrahmen, Khalil Ghedira, Alia Zehani, Skander Kedous, Sofiene Bouali

    Giant cell tumor (GCT) of bone is a benign tumor originating from undifferentiated mesenchymal cells of the bone marrow. It most commonly arises in the epiphyseal regions of long bones. The skull represents an extremely rare location for GCT. Certain radiologic features involving the temporal or sphenoid bone strongly suggest this diagnosis. Skull GCT is a locally aggressive condition, posing surgical challenges and exposing the patient to a considerable risk of recurrence. In this article, we describe the diagnosis and surgical management of two patients with GCT of the temporal bone. The first patient is a 24-year-old man who presented with progressive left temporal swelling and hearing loss. Computed tomography revealed a 5.6× 4.6× 4.2 cm osteolytic lesion of the left temporal bone. The patient underwent neartotal resection and exhibited no recurrence after 10 years of follow-up. The second patient was a 55-year-old man presenting with gradual hearing loss in the right ear and trismus. Computed tomography showed a 4.7× 4.2× 3 cm temporo-sphenoidal erosive lesion. Complete surgical resection was performed with a favorable outcome and no recurrence.